For HR+/HER2- metastatic breast cancer (mBC)
Then again, so were videotapes
While 1L SOC has advanced to include CDK4/6i, aromatase inhibitors (AIs) have remained the most used endocrine therapy (ET) backbone since their introduction over 2 decades ago. How can we modernize our understanding of what’s limiting patients’ time on their 1L ET backbone?1-3
Time on 1L is key for patients’ disease4-12
1L treatment response is critical as outcomes worsen in later lines, elevating the need for modern approaches for ETs in 1L.
AI use may limit ET efficacy in 1L13-15
AIs may leave the estrogen receptor intact and susceptible to estrogen-independent activation and resistance.1,16,17
>2 decades of innovation stagnation in 1L ET1,3,18
1L ET backbone in HR+/HER2- mBC has had little innovation in 20 years, yet cancer keeps evolving.
1L=first line; CDK4/6i=cyclin-dependent kinase 4/6 inhibitor; HER2–=human epidermal growth factor receptor 2 negative; HR+=hormone receptor positive; SOC=standard of care.
